Economic Analysis of Alvimopan—A Clarification and Commentary
dc.contributor.author | Bell, Timothy J. | en_US |
dc.contributor.author | Poston, Sara A. | en_US |
dc.contributor.author | Kraft, Michael D. | en_US |
dc.contributor.author | Senagore, Anthony J. | en_US |
dc.contributor.author | Techner, Lee | en_US |
dc.date.accessioned | 2013-06-18T18:33:14Z | |
dc.date.available | 2014-07-01T15:53:23Z | en_US |
dc.date.issued | 2013-05 | en_US |
dc.identifier.citation | Bell, Timothy J.; Poston, Sara A.; Kraft, Michael D.; Senagore, Anthony J.; Techner, Lee (2013). "Economic Analysis of Alvimopan—A Clarification and Commentary." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33(5): e81-e82. <http://hdl.handle.net/2027.42/98345> | en_US |
dc.identifier.issn | 0277-0008 | en_US |
dc.identifier.issn | 1875-9114 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/98345 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Gastroenterology | en_US |
dc.subject.other | Surgery Outcomes | en_US |
dc.subject.other | Ileus | en_US |
dc.subject.other | Alvimopan | en_US |
dc.title | Economic Analysis of Alvimopan—A Clarification and Commentary | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 23065817 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/98345/1/phar1193.pdf | |
dc.identifier.doi | 10.1002/phar.1193 | en_US |
dc.identifier.source | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | en_US |
dc.identifier.citedreference | Touchette DR, Yang Y, Tiryaki F, Galanter WL. Economic analysis of alvimopan for prevention and management of postoperative ileus. Pharmacotherapy 2012; 32 ( 2 ): 120 – 8. | en_US |
dc.identifier.citedreference | Bell TJ, Poston SA, Kraft MD, Senagore AJ, Delaney CP, Techner L. Economic analysis of alvimopan in North American phase III efficacy trials. Am J Health Syst Pharm 2009; 66: 1362 – 8. | en_US |
dc.identifier.citedreference | Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg 2008; 143: 1098 – 105. | en_US |
dc.identifier.citedreference | Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005; 48: 1114 – 25; discussion 1125–6; author reply 1127–9. | en_US |
dc.identifier.citedreference | Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu‐opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double‐blind, controlled study. Surg Endosc 2006; 20: 64 – 70. | en_US |
dc.identifier.citedreference | Absher RK, Gerkin TM, Banares LW. Alvimopan use in laparoscopic and open bowel resections: initial clinical results in a large community hospital system. Ann Pharmacother 2010; 44: 1701 – 8. | en_US |
dc.identifier.citedreference | Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting [mu] opioid antagonist: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004; 240: 728 – 34, discussion 734–5. | en_US |
dc.identifier.citedreference | Poston S, Broder MS, Gibbons MM, et al. Impact of alvimopan (Entereg) on hospital costs after bowel resection: results from a large inpatient database. P & T 2011; 36: 209 – 20. | en_US |
dc.identifier.citedreference | Delaney CP, Craver C, Gibbons MM, et al. Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched‐cohort study in patients undergoing bowel resection. Ann Surg 2012; 255: 731 – 8. | en_US |
dc.identifier.citedreference | Büchler MW, Seiler CM, Monson JRT, et al. Clinical trial: alvimopan for the management of post‐operative ileus after abdominal surgery: results of an international randomized, double‐blind, multicentre, placebo‐controlled clinical study. Aliment Pharmacol Ther 2008; 28: 312 – 25. | en_US |
dc.identifier.citedreference | Adolor Corporation. Entereg (alvimopan) capsules for postoperative ileus (POI), FDA advisory panel briefing document, 14 December 2007. Available from http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4336b1-02-Adolor.pdf. Accessed May 4, 2012. | en_US |
dc.identifier.citedreference | Wolff BG, Weese JL, Ludwig KA, et al. Postoperative ileus–related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg 2007; 204: 609 – 16. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.